Physician profile
Michael Pack
NPI 1508822966
$30,950.01
in general payments reported to CMS, 2019-2025
36 companies · $5,062 in 2025
The $5,062 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,955 · 2020: $852 · 2021: $1,745 · 2022: $3,542 · 2023: $3,239 · 2024: $14K · 2025: $5,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $5,351 · Travel and Lodging: $2,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,750.00 |
| Food and Beverage | $5,351.11 |
| Travel and Lodging | $2,754.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15,225.57 | 2019-2025 | Watchman Access System, Watchman, Watchman Flx |
| Abbott Laboratories | $6,317.04 | 2019-2025 | Aveir, Jot Dx, Assurity |
| Novartis Pharmaceuticals Corporation | $1,606.04 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,309.21 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,059.48 | 2019-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $1,026.10 | 2019 | |
| Pfizer INC. | $640.72 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $593.45 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $502.79 | 2019-2025 | Farxiga, Brilinta, Andexxa |
| Amgen INC. | $445.38 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $272.35 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $204.57 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $184.38 | 2022-2025 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $136.48 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $129.04 | 2020-2025 | Opsynvi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $127.31 | 2019-2024 | Evkeeza |
| Shockwave Medical, INC | $123.92 | 2025 | |
| Medtronic, INC. | $121.08 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $106.43 | 2023 | Optimizer |
| Cardiva Medical, INC. | $103.79 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Optowire, Cardiva Vascade 6/7f Vcs |
| Bayer Healthcare Pharmaceuticals INC. | $95.11 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $75.63 | 2019-2023 | |
| Lexicon Pharmaceuticals, INC. | $72.77 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $71.85 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $70.93 | 2021-2025 | Onpattro |
| Daiichi Sankyo INC. | $52.96 | 2020-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $50.60 | 2021-2023 | Arcalyst |
| Edwards Lifesciences Corporation | $49.61 | 2021-2023 | Sapien 3 Ultra Resilia |
| Bridgebio Pharma, INC. | $35.12 | 2025 | Attruby |
| Novo Nordisk INC | $29.63 | 2025 | Rybelsus, Ozempic, Wegovy |
| Chiesi USA, INC. | $23.63 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $21.04 | 2024 | Arcalyst |
| Ge Healthcare | $17.84 | 2020 | |
| Ethicon US, LLC | $17.59 | 2025 | Stratafix, Surgiflo Hemostatic Matrix |
| Cordis US Corp. | $16.18 | 2023 | Mynx Control |
| Livanova USA, INC. | $14.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.